secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cadrenal Therapeutics, Inc. (CVKD)
CIK:        0001937993
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001213900-25-107949
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cadrenal Therapeutics Q3 2025 net loss $2.7M; advances tecarfarin and frunexian pipeline
--------------------------------------------------------------------------------

- Net loss of $2.7M for Q3 2025 vs $2.4M in Q3 2024; cash and equivalents $3.9M as of Sept 30.
- R&D expense $0.7M (down from $0.8M); G&A expense $2.0M (up from $1.7M) year-over-year.
- Completed cGMP manufacturing of tecarfarin; ongoing Phase 2 LVAD study with Abbott.
- Acquired eXIthera Pharmaceuticals assets in Sept 2025, including frunexian, a Phase 2-ready IV Factor XIa inhibitor.
- ~2.1M common shares outstanding as of Sept 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025107949/0001213900-25-107949-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937993/000121390025107949/ea0264724-8k_cadrenal.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-107949

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer